Dealing with a 2027 Maturity early
Haleon's August 2026 activity in the Debt markets attracted less attention than its half-year results, but it addressed a meaningful item on the balance sheet: close to US$2 billion of notes due in March 2027. The consumer health company raised US$2 billion of new bonds and launched a tender offer for the older notes. How it approached this refinancing, and what its operating performance says about its capacity to carry debt, is examined here.
The business
Haleon plc (LSE:HLN) is a consumer health company whose brands span oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health and therapeutic skin health. Its shares trade on the London Stock Exchange under the ticker HLN, and it also has a listing in New York. Brian McNamara is chief executive. The company sells over-the-counter and everyday health products worldwide, reporting across North America, EMEA and Latin America, and Asia-Pacific.
The refinancing announcements
On 11 August 2026, Haleon announced a cash tender offer, made through its Wholly Owned Subsidiary Haleon US Capital LLC, for the outstanding US$1,999,350,000 of 3.375% fixed rate notes due March 2027. On 13 August 2026, the same subsidiary priced a US$2 billion bond in three tranches: US$600 million maturing in 2029 with a 4.625% coupon, US$600 million maturing in 2031 at 4.875%, and US$800 million maturing in 2036 at 5.375%. Haleon plc acts as full and unconditional guarantor. The company said proceeds would be used to repurchase the 2027 notes in whole or in part and for general corporate purposes, with settlement on 21 August 2026. A further announcement on 19 August 2026 reported the pricing, expiration and result of the tender; the detailed acceptance figures were contained in an attached document not reviewed for this article.
The effect is to replace a single near-term maturity with debt spread across 2029, 2031 and 2036, although at coupons above the 3.375% on the notes being retired.
Operating and financial performance
The half-year results published on 30 July 2026 provide the backdrop. Revenue for the six months to 30 June 2026 was £5,602 million, with organic growth of 2.6%. Oral health led with organic growth of 7.3%, while respiratory health declined 4.7%. By region, Asia-Pacific grew 4.7% organically, North America 2.0% and EMEA and Latin America 1.9%.
Adjusted operating profit rose 8.2% at constant currency to £1,364 million, with the adjusted Operating Margin at 24.3%. Reported operating profit was £1,172 million. Adjusted Diluted Earnings per Share increased 12.0% to 10.3p, free Cash Flow rose by £35 million to £769 million, and net debt stood at 2.5 times adjusted EBITDA. The Interim Dividend increased 9% to 2.4p, and £457 million of a £500 million buyback allocation had been completed. McNamara said the company "delivered a good first half performance in what remains a challenging consumer environment."
Risks and points to watch
Higher coupons on the new bonds will add to interest costs compared with the notes they replace. Volume and mix were negative in North America and EMEA and Latin America, meaning growth there relied on pricing, which may be harder to sustain if consumers remain cautious. Respiratory health is sensitive to cold and flu seasons. Currency movements also affect reported results, as the reported-organic gap also indicates. Haleon guided to 3% to 5% organic revenue growth for 2026 and high single-digit adjusted operating profit growth at constant currency.
Conclusion
Haleon refinanced its March 2027 dollar notes by issuing a US$2 billion three-tranche bond and offering to buy back the older debt, spreading maturities further into the future at higher interest rates. Steady cash generation and margin expansion in the first half support that debt load. Delivery against 2026 growth guidance remains the key measure to follow.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...